AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25931216 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopping immunosuppressive agents (SD group)
Number of subjects: 104
Study 25931216 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not stop immunosuppressive drugs)
Number of subjects: 104
Study 25931216 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who survived pulmonary infection (both groups)
Number of subjects: 104
Study 23333785 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen (O2 group; n = 14)
Number of subjects: 85
Study 23333785 — intervention group
Group type: COMPARATOR
Intervention: air group (control; n = 40)
Number of subjects: 85
Study 21415171 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (HFD; 55-60E% fat, 25-30E% carbohydrate, and 15E% protein)
Number of subjects: 21
Study 21415171 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (ND; 25-35E% fat, 55-60E% carbohydrate, and 10-15E% protein)
Number of subjects: 21
Study 21415171 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (HFD) with lipid substrate (octanoyl-carnitine with or without ADP)
Number of subjects: 21
Study 21415171 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (HFD)
Number of subjects: 21
Study 19546869 — intervention group
Group type: EXPERIMENTAL
Intervention: Hunger condition (Study 1)
Number of subjects: 151
Study 19546869 — intervention group
Group type: EXPERIMENTAL
Intervention: Hunger condition (Study 2)
Number of subjects: 151
Study 19546869 — intervention group
Group type: COMPARATOR
Intervention: Sated condition (Study 1)
Number of subjects: 151
Study 19546869 — intervention group
Group type: COMPARATOR
Intervention: Sated condition (Study 2)
Number of subjects: 151
Study 17338710 — intervention group
Group type: EXPERIMENTAL
Intervention: NID 12 (12 of 16 intervals)
Number of subjects: 875
Study 17338710 — intervention group
Group type: COMPARATOR
Intervention: NID 18 (18 of 24 intervals)
Number of subjects: 875
Study 17338710 — intervention group
Group type: COMPARATOR
Intervention: Hypothetical NID 18 for NID 12 patients
Number of subjects: 875
Study 17338710 — intervention group
Group type: COMPARATOR
Intervention: Hypothetical NID 12 for NID 18 patients
Number of subjects: 875
Study 15037050 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptic face recognition
Number of subjects: 1
Study 15037050 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 1
Study 10655193 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine (2%, 0.4 ml)
Number of subjects: 50
Study 10655193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 10655193 — intervention group
Group type: COMPARATOR
Intervention: Mepivacaine vs Placebo
Number of subjects: 50
Study 10655193 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine
Number of subjects: 50
Study 8882471 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole and tripotassium dicitrato bismuthate combined with ranitidine and antacid (group 1)
Number of subjects: 736
Study 8882471 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine and antacid (group 2)
Number of subjects: 736
Study 8882471 — intervention group
Group type: COMPARATOR
Intervention: H2-receptor antagonist and antacid (group 3, H. pylori-negative patients)
Number of subjects: 736
Study 1986509 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 14
Study 1986509 — intervention group
Group type: COMPARATOR
Intervention: Room air (16% oxygen)
Number of subjects: 14
Study 6669871 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment (rest in splints, non‐steroidal anti‐inflammatory drugs, gold or anti‐malaria agent) for 4-5 months
Number of subjects: 121
Study 6669871 — intervention group
Group type: EXPERIMENTAL
Intervention: Synovectomy surgery
Number of subjects: 121
Study 6669871 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-surgical treatment)
Number of subjects: 121
Study 6669871 — intervention group
Group type: COMPARATOR
Intervention: All patients (surgical and conservative treatment)
Number of subjects: 121
Study 31535367 — intervention group
Group type: EXPERIMENTAL
Intervention: Levcromakalim
Number of subjects: 20
Study 31535367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29405368 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive telephone support (daily calls for up to 14 days after discharge)
Number of subjects: 493
Study 29405368 — intervention group
Group type: COMPARATOR
Intervention: Control group (could initiate telephone contact themselves)
Number of subjects: 493
Study 26028355 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced behavioral counseling (FRESH)
Number of subjects: 300
Study 26028355 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard care (control)
Number of subjects: 300
Study 22828087 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Office Blood Pressure (AOBP)
Number of subjects: 252
Study 22828087 — intervention group
Group type: COMPARATOR
Intervention: Conventional Manual Office Blood Pressure (MOBP)
Number of subjects: 252
Study 22828087 — intervention group
Group type: EXPERIMENTAL
Intervention: AOBP
Number of subjects: 252
Study 22828087 — intervention group
Group type: COMPARATOR
Intervention: MOBP
Number of subjects: 252
Study 19622200 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to the letter A before a task
Number of subjects: 131
Study 19622200 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to the letter F before a task
Number of subjects: 131
Study 19622200 — intervention group
Group type: COMPARATOR
Intervention: Exposure to the neutral letter J (control condition) in Expt 2
Number of subjects: 131
Study 18403742 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART Arm with electromyography‐triggered electrical stimulation
Number of subjects: 42
Study 18403742 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART Arm alone
Number of subjects: 42
Study 18403742 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 42
Study 15809569 — intervention group
Group type: EXPERIMENTAL
Intervention: 10K group (10,000 steps per day)
Number of subjects: 58
Study 15809569 — intervention group
Group type: COMPARATOR
Intervention: 30‐min group (brisk 30‐min walk)
Number of subjects: 58
Study 15809569 — intervention group
Group type: COMPARATOR
Intervention: 30‐min group (on days with a 30-min walk)
Number of subjects: 58
Study 15809569 — intervention group
Group type: COMPARATOR
Intervention: 30‐min group (on days without a 30-min walk)
Number of subjects: 58
Study 15809569 — intervention group
Group type: EXPERIMENTAL
Intervention: 10K group (on days with at least 10,000 steps)
Number of subjects: 58
Study 15809569 — intervention group
Group type: EXPERIMENTAL
Intervention: 10K group (on days without achieving target)
Number of subjects: 58
Study 12096707 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-managed smoking cessation program including physician advice, bedside education and counseling, take-home materials, nicotine replacement therapy, and post-discharge counseling calls.
Number of subjects: 2091
Study 12096707 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-managed smoking cessation program
Number of subjects: 2091
Study 10671699 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic treatment
Number of subjects: 60
Study 10671699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8906007 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal spray bromocriptine (0.8 mg)
Number of subjects: 18
Study 8906007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1679444 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine with a single-use brush
Number of subjects: 0
Study 1679444 — intervention group
Group type: COMPARATOR
Intervention: Povidone-iodine
Number of subjects: 0
Study 6498122 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate short-term maternal exercise (n = 14)
Number of subjects: 28
Study 6498122 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 14)
Number of subjects: 28
Study 30801983 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy total diet replacement (TDR) program
Number of subjects: 0
Study 30801983 — intervention group
Group type: COMPARATOR
Intervention: Nurse-led behavioral support
Number of subjects: 0
Study 30558159 — intervention group
Group type: EXPERIMENTAL
Intervention: WB+BM− (Wheat Bran without Barley)
Number of subjects: 60
Study 30558159 — intervention group
Group type: EXPERIMENTAL
Intervention: WB−BM+ (Barley without Wheat Bran)
Number of subjects: 60
Study 30558159 — intervention group
Group type: EXPERIMENTAL
Intervention: WB+BM+ (Wheat Bran and Barley)
Number of subjects: 60
Study 30558159 — intervention group
Group type: COMPARATOR
Intervention: WB−BM− (Control group with neither Wheat Bran nor Barley)
Number of subjects: 60
Study 26830468 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS181 (10 mg administered via dry particle inhaler on 3 consecutive days)
Number of subjects: 10
Study 26830468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 25332321 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-oil supplementation (1.5 g LC n-3 PUFAs/d)
Number of subjects: 84
Study 25332321 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 84
Study 22302719 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (10 mg daily for 3 days)
Number of subjects: 30
Study 22302719 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo for 3 days)
Number of subjects: 30
Study 22302719 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 30
Study 22302719 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 22302719 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole and Control
Number of subjects: 30
Study 20485335 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (1.0 mg b.i.d.)
Number of subjects: 124
Study 20485335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 17111121 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive glass (BG group)
Number of subjects: 20
Study 17111121 — intervention group
Group type: COMPARATOR
Intervention: Bioabsorbable membrane (BM group)
Number of subjects: 20
Study 17111121 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 17562750 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate soothing algorithm
Number of subjects: 182
Study 17562750 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular rate stabilization algorithm
Number of subjects: 182
Study 17562750 — intervention group
Group type: EXPERIMENTAL
Intervention: All on (rate soothing + ventricular rate stabilization + post-AF response)
Number of subjects: 182
Study 17562750 — intervention group
Group type: COMPARATOR
Intervention: All off (DDD 60)
Number of subjects: 182
Study 15550166 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-day small group seminar on medical interviewing
Number of subjects: 105
Study 15550166 — intervention group
Group type: COMPARATOR
Intervention: Control group (no seminar)
Number of subjects: 105
Study 11004108 — intervention group
Group type: EXPERIMENTAL
Intervention: Head mounted perimetry system
Number of subjects: 37
Study 11004108 — intervention group
Group type: COMPARATOR
Intervention: Confrontation visual field testing
Number of subjects: 37
Study 9178384 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical CPR (M-CPR)
Number of subjects: 12
Study 9178384 — intervention group
Group type: COMPARATOR
Intervention: Manual Standard CPR (S-CPR)
Number of subjects: 12
Study 9178384 — intervention group
Group type: COMPARATOR
Intervention: Active Compression-Decompression CPR (ACD-CPR)
Number of subjects: 12
Study 1491396 — intervention group
Group type: EXPERIMENTAL
Intervention: DecaDurabolin
Number of subjects: 18
Study 1491396 — intervention group
Group type: EXPERIMENTAL
Intervention: salmon calcitonin (sCT)
Number of subjects: 18
Study 1491396 — intervention group
Group type: COMPARATOR
Intervention: oral Ca (control)
Number of subjects: 18
Study 3888250 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 3 g amoxycillin
Number of subjects: 90
Study 3888250 — intervention group
Group type: COMPARATOR
Intervention: Conventional course of ampicillin over 7 days
Number of subjects: 90
Study 30272159 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-promoting interventions targeting social and environmental levels
Number of subjects: 35
Study 30332482 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 1.5 μg/kg
Number of subjects: 90
Study 30332482 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 2.0 μg/kg
Number of subjects: 90
Study 30332482 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 2.5 μg/kg
Number of subjects: 90
Study 27207411 — intervention group
Group type: EXPERIMENTAL
Intervention: DDS-1 strain of Lactobacillus acidophilus (1 dose daily for 4 weeks)
Number of subjects: 0
Study 27207411 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin, 1 dose daily for 4 weeks)
Number of subjects: 0
Study 24686106 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of interferon beta‐1a and glatiramer acetate
Number of subjects: 1008
Study 24686106 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta‐1a alone
Number of subjects: 1008
Study 24686106 — intervention group
Group type: COMPARATOR
Intervention: Glatiramer acetate alone
Number of subjects: 1008
Study 22331758 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 50-mg tablets (test formulation)
Number of subjects: 40
Study 22331758 — intervention group
Group type: COMPARATOR
Intervention: Bicalutamide 50-mg tablets (reference formulation)
Number of subjects: 40
Study 20558755 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NAME + ketorolac infusion
Number of subjects: 13
Study 20558755 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NAME infusion
Number of subjects: 13
Study 20558755 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 13
Study 20558755 — intervention group
Group type: COMPARATOR
Intervention: Control values
Number of subjects: 13
Study 17377860 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukodepletion (group A: n = 25)
Number of subjects: 50
Study 17377860 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B: n = 25)
Number of subjects: 50
Study 15617967 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary closure technique (Group 1) - hermetically suturing the flap
Number of subjects: 200
Study 15617967 — intervention group
Group type: COMPARATOR
Intervention: Secondary closure technique (Group 2) - removal of a 5-6 mm wedge of mucosa for secondary healing
Number of subjects: 200
Study 11891832 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (5 to 20mg per week)
Number of subjects: 44
Study 11891832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 10213296 — intervention group
Group type: EXPERIMENTAL
Intervention: MM + MNF (multi-nutrient fortifier)
Number of subjects: 25
Study 10213296 — intervention group
Group type: EXPERIMENTAL
Intervention: MM + CaGP (calcium and phosphorus alone)
Number of subjects: 25
Study 10213296 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-MM (mother's milk feeding group to 6 months)
Number of subjects: 25
Study 10213296 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-FF (formula feeding group)
Number of subjects: 25
Study 10213296 — intervention group
Group type: COMPARATOR
Intervention: PTF (preterm formula)
Number of subjects: 25
Study 8536087 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum consumption after meals (study group)
Number of subjects: 1281
Study 8536087 — intervention group
Group type: COMPARATOR
Intervention: Xylitol chewing gum consumption after meals (control group)
Number of subjects: 1281
Study 8536087 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily use of xylitol chewing gum (study group)
Number of subjects: 1281
Study 8536087 — intervention group
Group type: COMPARATOR
Intervention: Daily use of xylitol chewing gum (control group)
Number of subjects: 1281
Study 8536087 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about xylitol (study group)
Number of subjects: 1281
Study 2798632 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial daylight (2500 lux) from 20.00 to 23.00 and from 07.00 to 10.00 hours
Number of subjects: 10
Study 2798632 — intervention group
Group type: COMPARATOR
Intervention: Red light (300 lux) from 20.00 to 23.00 and from 07.00 to 10.00 hours
Number of subjects: 10
Study 2798632 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial daylight (2500 lux) from 22.00 to 23.00 and from 07.00 to 08.00 hours
Number of subjects: 10
Study 334336 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g/day)
Number of subjects: 45
Study 334336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 31015587 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of levodopa
Number of subjects: 31
Study 31015587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 29906570 — intervention group
Group type: EXPERIMENTAL
Intervention: FOND-O (Fosaprepitant, Ondansetron, Dexamethasone + Olanzapine 10 mg)
Number of subjects: 101
Study 29906570 — intervention group
Group type: COMPARATOR
Intervention: FOND (Fosaprepitant, Ondansetron, Dexamethasone)
Number of subjects: 101
Study 27713633 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally laparoscopic procedure (n=14)
Number of subjects: 30
Study 27713633 — intervention group
Group type: COMPARATOR
Intervention: Open surgical procedure (n=16)
Number of subjects: 30
Study 25414047 — intervention group
Group type: EXPERIMENTAL
Intervention: PS+PA (300 mg PS + 240 mg PA/day)
Number of subjects: 53
Study 25414047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 22309303 — intervention group
Group type: EXPERIMENTAL
Intervention: SafeR
Number of subjects: 422
Study 22309303 — intervention group
Group type: COMPARATOR
Intervention: DDD/AMC
Number of subjects: 422
Study 22309303 — intervention group
Group type: COMPARATOR
Intervention: DDD/LD
Number of subjects: 422
Study 21039042 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay health worker home visit
Number of subjects: 234
Study 21039042 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 234
Study 18211754 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with 'Dermatophagoides Farinae Drops' (n = 139)
Number of subjects: 278
Study 18211754 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 139)
Number of subjects: 278
Study 15530583 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight control advice
Number of subjects: 255
Study 15530583 — intervention group
Group type: EXPERIMENTAL
Intervention: Information on health benefits of weight loss
Number of subjects: 255
Study 15530583 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to increase physical activity
Number of subjects: 255
Study 15530583 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-delivered weight control advice
Number of subjects: 255
Study 15530583 — intervention group
Group type: EXPERIMENTAL
Intervention: Education about weight loss
Number of subjects: 255
Study 12819512 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic immunization with inactivated envelope-depleted HIV-1 coupled with incomplete Freund's adjuvant (IFA)
Number of subjects: 9
Study 12819512 — intervention group
Group type: COMPARATOR
Intervention: Placebo (IFA alone)
Number of subjects: 9
Study 12819512 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic immunization
Number of subjects: 9
Study 10903599 — intervention group
Group type: EXPERIMENTAL
Intervention: rBPI21 treatment
Number of subjects: 0
Study 10903599 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 10903599 — intervention group
Group type: COMPARATOR
Intervention: Control group (other major abdominal surgeries)
Number of subjects: 0
Study 8752803 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg three times a day)
Number of subjects: 298
Study 8752803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study 1990951 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline 10 mg/kg/day orally for 30 days
Number of subjects: 14
Study 1990951 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 30 days
Number of subjects: 14
Study 6886255 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihistamine (4 mg of brompheniramine maleate)
Number of subjects: 20
Study 6886255 — intervention group
Group type: EXPERIMENTAL
Intervention: Decongestant-antihistamine combination (4 mg of brompheniramine maleate, 5 mg of phenylephrine HCl, 5 mg of phenylpropanolamine HCl)
Number of subjects: 20
Study 6886255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6886255 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (premedication)
Number of subjects: 20
Study 30610143 — intervention group
Group type: EXPERIMENTAL
Intervention: After-Visit Summary (AVS) provided to patients after each clinic visit
Number of subjects: 250
Study 30610143 — intervention group
Group type: EXPERIMENTAL
Intervention: After-Visit Summary (AVS) provided in patients' first language
Number of subjects: 250
Study 30610143 — intervention group
Group type: EXPERIMENTAL
Intervention: After-Visit Summary (AVS) meaningfulness
Number of subjects: 250
Study 30610143 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for nonmeaningful AVS
Number of subjects: 250
Study 29941497 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth
Number of subjects: 421
Study 29941497 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with diabetes
Number of subjects: 421
Study 27104905 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth accelerometer-based physical activity prescription
Number of subjects: 30
Study 25262324 — intervention group
Group type: EXPERIMENTAL
Intervention: Push as-fast-as-you-can (PF)
Number of subjects: 42
Study 25262324 — intervention group
Group type: COMPARATOR
Intervention: 100 compressions per minute (100-cpm)
Number of subjects: 42
Study 22162508 — intervention group
Group type: EXPERIMENTAL
Intervention: valproic acid (300 mg bid) with early or late addition of lacosamide (200 mg bid)
Number of subjects: 32